Key Takeaways Exact Sciences is driving growth through Cologuard, Oncotype DX and new product launches.EXAS targets 15% revenue growth, $150M savings by 2026 and stronger operating margins.Macroeconomic pressures and fierce competition remain key challenges for Exact Sciences.Exact Sciences Corporation (EXAS) is well-poised to grow in the coming quarters, courtesy of the ongoing momentum in its Cologuard and Oncotype DX tests. The company continues to invest in its pipeline to develop innovative solutions f ...

It took years for Sundas Hashmi to tell her children about her terminal cancer diagnosis. This is how she handled it. https://t.co/Jc2r7wyLcV ...

Financial Performance & Growth - Exact Sciences reported total revenue of $2.76 billion in 2024, a 10% year-over-year increase[7] - Adjusted EBITDA for 2024 was $323 million, up 48% year-over-year[7] - The company anticipates total revenue between $3.07 billion and $3.12 billion in 2025, representing a 12% increase at the midpoint[47] - Screening revenue in 2024 was $2.104 billion and is projected to be between $2.39 billion and $2.425 billion in 2025, a 14% increase at the midpoint[20, 47] - Precision Oncology revenue in 2024 was $655 million and is projected to be between $680 million and $695 million in 2025, a 5% increase at the midpoint[29, 47] - The company is targeting approximately 15% compounded annual revenue growth from 2022-2027 and over 20% adjusted EBITDA margin in 2027[50, 52] Product Development & Market Opportunity - Exact Sciences is launching three new advanced cancer tests in 2025: Oncodetect for molecular residual disease ($18 billion TAM), Cancerguard for multi-cancer screening ($25 billion TAM), and Cologuard Plus for colon cancer screening ($15 billion TAM)[4, 5] - Cologuard has saved the U S healthcare system $22 billion[16] - Cancerguard could reduce cancer mortality by 17%[41]